Background and Purpose-We aimed to analyze the frequency of persistent hyperglycemia (PH), its implications for outcome, and to document the inpatient management of hyperglycemia. Methods-Post hoc analysis of the GLIAS (Glycemia in Acute Stroke) study, a multicenter, prospective, and observational cohort study of 476 acute ischemic stroke patients. Capillary finger-prick glucose was determined on admission and during the first 48 hours. We defined PH was defined as at least 2 values Ն155 mg/dL. Outcome (modified Rankin Scale) was evaluated at 3 months. Results-PH developed in 117 patients (24.7%). PH was associated with poorer outcome (modified Rankin Scale score Ͼ2: 56.2% vs 28.1%; PϽ0.01) and higher mortality (26.7% vs 5.9%; PϽ0.01) than those with glycemia Ͻ155 mg/dL. PH Ն155 mg/dL was associated with a 4-fold increase in the odds of poor outcome at 3 months (odds ratio, 4.7; 95% confidence interval, 2.2-10.2) after adjustment for age, gender, hypertension, diabetes, stroke severity, admission glycemia, and infarct volume. Only 20% of patients with hyperglycemia Ն155 mg/dL received insulin on admission, with a progressive increase in the use of insulin during the following 48 hours. However, 114 (39.1%) out of 291 patients who received corrective treatment for hyperglycemia still had levels Ն155 mg/dL. Conclusions-PH Ն155 mg/dL is a common observation in acute ischemic stroke patients that is associated with poorer outcome and higher mortality. Almost 40% of patients maintained levels Ն155 mg/dL despite corrective treatment. (Stroke. 2010;41:2362-2365.)
H yperglycemia is a common finding in acute ischemic stroke (IS) patients, and it has been associated with poor outcome. Recent studies have demonstrated that not only admission glucose values but also the development of hyperglycemia on serial glucose evaluations are associated with poor outcome. 1, 2 Our goal was to analyze the frequency of persistent hyperglycemia (PH), its implications for stroke outcome, and to document the inpatient management of hyperglycemia.
Subjects and Methods
We conducted a post hoc analysis of the GLIAS (Glycemia in Acute Stroke) study. Full details of the rationale and design of the GLIAS study have been described elsewhere. 1 In brief, the GLIAS study is a multicenter, prospective, and observational study. Consecutive patients with IS Ͻ24 hours from symptom onset were included.
For the purpose of this analysis, we recorded capillary finger-prick glucose on admission and 3 times per day during the first 2 days. We considered hyperglycemia as levels Ն155 mg/dL, because that was the threshold level associated with poor outcome in the GLIAS study, 1 and we considered PH as the demonstration of at least 2 values Ն155 mg/dL within the first 48 hours. We recorded all corrective treatments to normalize glycemia applied to each patient at the discretion of the treating physician. For the purpose of our analysis, the principal outcome measure was poor outcome, which was defined as modified Rankin Scale score Ͼ2 at 3 months.
The statistical analysis was performed in SPSS 12.0 (SPSS Inc) and SAS Enterprise Guide 3.0. Proportions between groups were compared using the 2 test, whereas quantitative variables between groups were compared using analysis of variance or Kruskal-Wallis tests depending on distribution. Univariate and multivariate adjusted forward stepwise logistic regression models were constructed to adjust for the effect of PH Ն155 mg/dL within the first 48 hours on outcome for factors that showed significant differences between groups. Survival time was estimated from Kaplan-Meier survival curves and tested for statistical significance with a log-rank test. Estimated hazard ratio and 95% CI were calculated by fitting a Cox proportional hazards survival model.
Results
A total of 476 inpatients with acute IS were included in the GLIAS study. A total of 113 patients (23.9%) had hyperglycemia Ͼ155 mg/dL on admission, and 86 of them (76.1%) had PH Ͼ155 mg/dL within the first 48 hours of stroke onset. In the group of 363 patients with levels Ͻ155 mg/dL on admission, 64 (17.6%) had hyperglycemia Ͼ155 mg/dL in subsequent evaluations and in 31 PH was demonstrated. Thus, PH was found in 117 patients (24.7% of total sample) and isolated hyperglycemia was found in 60 (12.6%). Demographic data, risk factors, and stroke etiologic subtypes of patients according to capillary glucose levels within the first 48 hour are shown in the Table. A total of 291 patients received corrective treatment to normalize glycemia. Figure 1 shows the temporal profile of glucose management. It is noteworthy that the majority of patients with hyperglycemia Ն155 mg/dL on admission received no corrective treatment. The frequency of treatment increased at the subsequent time points evaluated. However, in 114 patients (39.1%) persistent capillary glucose levels Ն155 mg/dL were found after treatment.
Patients with PH Ն155 mg/dL had poorer outcome than those with levels Ͻ155 mg/dL, although there were no Outcome data were based on data from 411 patients who completed the follow-up period. *PϽ0.05 for comparison between the 3 groups in the following variables: arterial hypertension, diabetes mellitus, stroke severity, capillar glucose levels on admission, infarct volume, and time from stroke onset to study inclusion.
†PϽ0.01 for the comparison between the glycemia group Ͻ155 mg/dL and the persistent hyperglycemia group Ն155 mg/dL. CI indicates cerebral infarction; CNS, Canadian Neurological Scale; SBP, systolic blood pressure.
Fuentes et al Persistent Hyperglycemia and Stroke 2363
differences when compared to patients with isolated hyperglycemia Ն155 mg/dL (Table) . The multiple logistic regression analysis showed that PH Ն155 mg/dL was an independent predictive factor (OR, 4.76; 95% CI, 2.20 -10.29) of poor outcome at 3 months after adjustment for age, gender, stroke severity, infarct volume, and isolated hyperglycemia Ն155 mg/dL. Kaplan-Meier survival curves showed higher mortality at 3 months in the group of patients with PH Ͼ155 mg/dL (Figure 2 ). The Cox proportional hazards survival model confirmed the prognostic role of PH Ͼ155 mg/dL compared with glucose levels Ͻ155 mg/dL (hazard ratio, 3.94; 95% CI, 2.08 -7.46) after adjustment for isolated hyperglycemia and stroke severity.
Discussion
Our study demonstrates that PH Ն155 mg/dL is a common observation in acute IS patients, affecting up to 25%, and it is also found in patients with levels Ͻ155 mg/dL on admission. A previous study conducting serial MRI assessments in 25 acute IS patients showed that PH was associated with infarct expansion and poorer outcome. 2 In addition, a post hoc analysis of ECASS II also suggested the higher prognostic value of hyperglycemia dynamics as opposed to a single glucose measurement. 3 Our study shows the deleterious effect of PH over isolated hyperglycemia. Because there is heterogeneity between studies in the definition of PH, and because our definition was arbitrary, although based on the results of a multicenter observational study, a prospective evaluation of the concept of PH is needed.
There is suboptimal management of hyperglycemia in IS patients. In a retrospective analysis of 656 IS patients, up to 43% of hyperglycemic patients received no diabetic medications during their hospital stay. 4 In our study, up to 97.5% of PH patients received some corrective treatment. This high implementation of acute stroke management guidelines reinforces its validity. Nevertheless, we found a very low rate of therapy for hyperglycemic patients on admission, and it is clear that more effort to optimize glucose control is needed.
Although results from trials on intensive glucose reduction in stroke patients are controversial, 5 normalization of blood glucose may prevent the deleterious effect of hyperglycemia in IS patients. This was suggested in a retrospective analysis showing that patients with controlled hyperglycemia had significantly lower mortality rates than those with persistent hyperglycemia and similar rates as those with persistent euglycemia. 6 Although the GLIAS study was not specifically designed to evaluate the efficacy of treatment, its design as a prospective and multicenter study allows the analysis of current patterns of glycemic control as well as the glucose levels achieved. It would be expected that the high frequency of administration of corrective treatments would result in better glycemia levels, but this was not true in up to 39% patients.
In conclusion, PH Ն155 mg/dL is a common observation in acute IS patients that is associated with poorer outcome and higher mortality. Almost 40% of patients maintained levels Ն155 mg/dL despite corrective treatment. Future research should focus on optimization of glycemic control in acute IS patients.
